期刊
VACCINE
卷 26, 期 23, 页码 2860-2872出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2008.03.044
关键词
vaccinia; smallpox vaccine; E3L
资金
- NIAID NIH HHS [AI 66501, AI66326, AI52347, R01 AI052347-02, U01 AI066326-03, U01 AI066326-01, U01 AI066326-02S1, U01 AI057303-05, R01 AI052347-04, R01 AI066501, U01 AI066326, R01 AI052347, U01 AI057303, R01 AI052347-01A1, U01 AI057303-02, U01 AI057303-03, U01 AI057303-01, R01 AI052347-03, U01 AI057303-04, R01 AI052347-05, U01 AI066326-02] Funding Source: Medline
In this study, we evaluated the efficacy of vaccinia virus (VACV) containing mutations in the E3L virulence gene to protect mice against a lethal poxvirus challenge after vaccination by scarification. VACV strains with mutations in the E3L gene had significantly decreased pathogenicity, even in immune deficient mice, yet retained the ability to produce a potent Th1-dominated immune response in mice after vaccination by scarification, while protecting against challenge with wild type, pathogenic VACV. Initial experiments were done using the mouse-adapted, neurovirulent Western Reserve (WR) strain of vaccinia virus. Testing of the full E3L deletion mutation in the Copenhagen and NYCBH strains of VACV, which are more appropriate for use in humans, produced similar results. These results suggest that highly attenuated strains of VACV containing mutations in E3L have the potential for use as scarification administered vaccines. (c) 2008 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据